Abstract
Thalidomide (α-N-phthalimidoglutarimide) was a widely used drug in the late 1950s as a hypnotic/ sedative agent. Thalidomide was subsequently withdrawn from the market due to teratogenicity in the early 1960s. Surprisingly, even after the initial impact of the thalidomide disaster, the drug was still used in the therapy of many diseases, and research studies in the field of thalidomide derivatives have significantly increased because of its tumor necrosis factor (TNF-α) production regulating effect. Recently, novel thalidomide derivatives have been synthesized as anti-inflammatory lead -candidates. This review will summarize the recent development of thalidomide derivatives which possess antiinflammatory activity.
Keywords: Thalidomide, Phthalimide, TNF-α, TNF-α inhibitors, anti-inflammatory activity, immunomodulatory, autoimmune diseases, anti-angiogenic effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity
Volume: 9 Issue: 1
Author(s): Hulya Akgun and Irem Karamelekoglu
Affiliation:
Keywords: Thalidomide, Phthalimide, TNF-α, TNF-α inhibitors, anti-inflammatory activity, immunomodulatory, autoimmune diseases, anti-angiogenic effects
Abstract: Thalidomide (α-N-phthalimidoglutarimide) was a widely used drug in the late 1950s as a hypnotic/ sedative agent. Thalidomide was subsequently withdrawn from the market due to teratogenicity in the early 1960s. Surprisingly, even after the initial impact of the thalidomide disaster, the drug was still used in the therapy of many diseases, and research studies in the field of thalidomide derivatives have significantly increased because of its tumor necrosis factor (TNF-α) production regulating effect. Recently, novel thalidomide derivatives have been synthesized as anti-inflammatory lead -candidates. This review will summarize the recent development of thalidomide derivatives which possess antiinflammatory activity.
Export Options
About this article
Cite this article as:
Akgun Hulya and Karamelekoglu Irem, Recent Developments of Thalidomide Derivatives Possessing Anti-Inflammatory Activity, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (1) . https://dx.doi.org/10.2174/187152310790711647
DOI https://dx.doi.org/10.2174/187152310790711647 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MICA Molecules in Disease and Transplantation, a Double-Edged Sword?
Current Immunology Reviews (Discontinued) Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Melanoma
Current Cancer Therapy Reviews Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents